These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19451583)

  • 1. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons?
    Sarafidis PA; Bakris GL
    Ann Intern Med; 2009 May; 150(10):731-3. PubMed ID: 19451583
    [No Abstract]   [Full Text] [Related]  

  • 2. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults?
    O'Hare AM; Kaufman JS; Covinsky KE; Landefeld CS; McFarland LV; Larson EB
    Ann Intern Med; 2009 May; 150(10):717-24. PubMed ID: 19451579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination inhibition of the renin-angiotensin system: is more better?
    Krause MW; Fonseca VA; Shah SV
    Kidney Int; 2011 Aug; 80(3):245-55. PubMed ID: 21633407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How should renin-angiotensin system blockade be applied in chronic kidney disease for optimal renal protection?
    Zhang X; Hou FF
    Chin Med J (Engl); 2007 Feb; 120(3):243-5. PubMed ID: 17355830
    [No Abstract]   [Full Text] [Related]  

  • 5. Renin-angiotensin system blockade in older adults with chronic kidney disease: a review of the literature.
    Weiss JW; Thorp ML; O'Hare AM
    Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):413-9. PubMed ID: 20539228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric nephropathy.
    Zaffanello M; Franchini M; Fanos V
    Pharmacotherapy; 2008 Jan; 28(1):125-30. PubMed ID: 18154482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD.
    Jain AK; Cuerden MS; McLeod I; Hemmelgarn B; Akbari A; Tonelli M; Quinn RR; Oliver MJ; Garg AX
    Kidney Int; 2012 Jun; 81(12):1248-53. PubMed ID: 22437415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade.
    Griffin KA; Bidani AK
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1054-65. PubMed ID: 17699327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slowing nephropathy progression: focus on proteinuria reduction.
    Bakris GL
    Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S3-10. PubMed ID: 18178794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK; Epstein M
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract]   [Full Text] [Related]  

  • 13. [How I treat... by optimizing the blockade of the renin-angiotensin-aldosterone system].
    Schleich F; Krzesinski JM; Piérard L; Scheen AJ
    Rev Med Liege; 2008 Apr; 63(4):174-81. PubMed ID: 18575070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.
    Tsouli SG; Liberopoulos EN; Kiortsis DN; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):1-15. PubMed ID: 16703216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical trials of renin-angiotensin antagonists in Japan].
    Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):182-3. PubMed ID: 18421845
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
    Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
    Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of renin-angiotensin system inhibitors after coronary interventions in patients with the guideline-based indications: A report from a Japanese multicenter registry.
    Ikemura N; Sawano M; Miyata H; Ueda I; Numasawa Y; Noma S; Suzuki M; Momiyama Y; Maekawa Y; Fukuda K; Kohsaka S
    Int J Cardiol; 2016 Dec; 225():362-364. PubMed ID: 27756042
    [No Abstract]   [Full Text] [Related]  

  • 19. Uncritical acceptance of combination treatment of angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease trial results.
    Griffin KA; Bidani AK
    Hypertension; 2009 Jan; 53(1):e3; author reply e4. PubMed ID: 19047576
    [No Abstract]   [Full Text] [Related]  

  • 20. [Recent clinical evidences of RAS inhibitors on chronic kidney diseases].
    Suzuki H; Takenaka T
    Nihon Jinzo Gakkai Shi; 2010; 52(2):120-4. PubMed ID: 20415232
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.